# Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

> **NCT02564744** · PHASE2 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 100 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Debio 1562
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02564744
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-05
- **Primary completion:** 2021-01-13
- **Final completion:** 2021-06-25
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564744, "Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02564744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*